AML mRNA multivalent LPP nanoparticle vaccine (Stemirna Therapeutics/Ruijin Hospital)

N/A

Report date: 2026/01/23 11:09:12

Base Information

Drug NameAML mRNA multivalent LPP nanoparticle vaccine (Stemirna Therapeutics/Ruijin Hospital)
Drug Alias NamemRNA vaccine targeting AML mutant antigens (Stemirna Therapeutics/Ruijin Hospital)mRNA vaccine encoding AML mutant antigens (Stemirna Therapeutics/Ruijin Hospital)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesStemirna Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStemirna TherapeuticsShanghai Rui Jin Hospital
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A